Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: Polyspecificity at B-ring position

36Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

Abstract

A series of chalcones substituted by a quinoxaline unit at the B-ring were synthesized and tested as inhibitors of breast cancer resistance protein-mediated mitoxantrone efflux. These compounds appeared more efficient than analogs containing other B-ring substituents such as 2-naphthyl or 3,4-methylenedioxyphenyl while an intermediate inhibitory activity was obtained with a 1-naphthyl group. In all cases, two or three methoxy groups had to be present on the phenyl A-ring to produce a maximal inhibition. Molecular modeling indicated both electrostatic and steric positive contributions. A higher potency was observed when the 2-naphthyl or 3,4-methylenedioxyphenyl group was shifted to the A-ring and methoxy substituents were shifted to the phenyl B-ring, indicating preferences among polyspecificity of inhibition. © 2014 Winter et al.

Cite

CITATION STYLE

APA

Winter, E., Gozzi, G. J., Chiaradia-Delatorre, L. D., Daflon-Yunes, N., Terreux, R., Gauthier, C., … Di Pietro, A. (2014). Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: Polyspecificity at B-ring position. Drug Design, Development and Therapy, 8, 609–619. https://doi.org/10.2147/DDDT.S56625

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free